- Home
- DXR vs FLNA Comparison
DXR vs FLNA Comparison
Compare DXR & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | FLNA |
|---|---|---|
| Founded | 1970 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 61.8M |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DXR | FLNA |
|---|---|---|
| Price | $11.45 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.0K | ★ 234.9K |
| Earning Date | 02-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,446,345.00 | ★ $41,119,000.00 |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $0.67 |
| 52 Week High | $14.76 | $2.03 |
Technical Indicators
Market Signals| Indicator | DXR | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 30.26 |
| Support Level | $9.43 | N/A |
| Resistance Level | $12.08 | $0.99 |
| Average True Range (ATR) | 0.76 | 0.05 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 65.96 | 19.66 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About FLNA Filana Therapeutics Inc. Common Stock
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.